This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
FDA Approves Gilead (GILD) HIV Triple Therapy, Stock Up
by Zacks Equity Research
Gilead (GILD) gets a huge boost with the FDA's approval of its once-daily single tablet regimen (STR), Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF) for the treatment of HIV-1 infection.
Gilead (GILD) Beats on Q4 Earnings, 2018 View Lacks Lustre
by Zacks Equity Research
Gilead (GILD) topped earnings and sales expectations in the fourth quarter but the guidance for 2018 was disappointing due to further weakness in the HCV franchise.
The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Walt Disney, Chipotle, Snap and Gilead Sciences
New Quarterly Earnings Results for DIS, CMG, SNAP and More
by Mark Vickery
Will these companies reporting after the close -- DIS, CMG, SNAP and GILD -- catch a break in after-hours trading?
Gilead (GILD) Posts Earnings Beat, Total Product Sales See YoY Decline
by Madeleine Johnson
Gilead Sciences (GILD) just released its fourth quarter fiscal 2017 financial results, posting earnings of $1.78 per share and revenues of $5.95 billion. Shares are down 2.4% to $78.50 in trading shortly after as a result.
Gilead's (GILD) HCV Segment to Decline Further in Q4 Earnings?
by Zacks Equity Research
Gilead's HCV franchise is under significant pressure due to increasing competition and the decline in franchise sales is expected to impact fourth-quarter results.
Will Gilead (GILD) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
Biotech bigwig Gilead Sciences (GILD) Q4 results are expected to be adversely impacted by the decline in HCV market share.
Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi
by Arpita Dutt
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Celgene (CELG) Q4 Earnings & Sales Beat on Solid Revlimid
by Zacks Equity Research
Celgene's (CELG) fourth-quarter results beat on both sales and earnings driven by solid growth in Revlimid and pick up in Otezla sales after a slowdown.
Bluebird Up on Buyout Speculation After Celgene/Juno Deal
by Zacks Equity Research
Bluebird Bio (BLUE) appears to be solid takeover target, with more and more companies expressing interest in the CAR-T space, especially after Celgene's acquisition of Juno Therapeutics.
Celgene (CELG) to Acquire Juno Therapeutics for $9 Billion
by Zacks Equity Research
Celgene is set to acquire Juno Therapeutics for $87 per share or a total value of $9 billion to strengthen its position in the cellular immunotherapy space.
Gilead Collaborates with Pfizer for Yescarta Combo Study
by Zacks Equity Research
Kite, a Gilead Company (GILD), announced that it inked a clinical trial collaboration with Pfizer, for combination study.
The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, JPMorgan, AbbVie, Gilead and Simon Property Group
Juno Hits 52-Week High on Celgene's Rumored Buyout Interest
by Zacks Equity Research
Juno Therapeutics, Inc.'s (JUNO) shares hit a 52 week high on rumors of the company being acquired by Celgene Corporation.
Novartis sBLA for CAR-T Therapy Kymriah Accepted by FDA
by Zacks Equity Research
Novartis (NVS) gets a significant boost with the FDA approval of CAR-T Therapy Kymriah and the company is now looking to expand the therapy's label.
3 Top-Ranked Drug Stocks that are Broker Favorites
by Arpita Dutt
With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.
Top Research Reports for Apple, JPMorgan & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV).
Is Celgene (CELG) Looking to Take Over Juno Therapeutics?
by Zacks Equity Research
There are reports that Celgene (CELG) is in talks to acquire Juno Therapeutics to strengthen its portfolio given the recent series of setbacks.
Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News
by Arpita Dutt
Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.
Can Biotech Keep Last Year's Momentum Alive in 2018?
by Zacks Equity Research
The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus
by Arpita Dutt
Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.
Galapagos Reports Topline Data From Osteoarthritis Study
by Zacks Equity Research
Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.
Celgene to Acquire Impact Biomedicines to Boost Pipeline
by Zacks Equity Research
Celgene (CELG) announced that it will acquire Impact Biomedicines to bolster its oncology pipeline given the recent series of setbacks.
3 Biotech and Pharma Stocks with FDA Catalysts this January
by Arpita Dutt
2017 saw the FDA approving 46 novel drugs as well as path-breaking treatments like Novartis's (NVS) Kymriah and Gilead's Yescarta. Here is a look at three companies expecting a decision this January.
Intercept (ICPT) Stock Loses Sheen in 2017: What Lies Ahead?
by Zacks Equity Research
Intercept (ICPT) had a tough time in 2017 after news of death were out related to lead drug's Ocaliva's dosing. We do not expect a phenomenal revival in 2018 either.